Slide 1

760 / 1631

RELEVANCE: OVERALL SURVIVAL (IMMATURE; ITT)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
OS Probability
R 2
R-chemo
0 6 12 18 24 30 36 42 48 54
Months from Randomization
60 66
513 499 491 486 479 459 312 194 105 24 0
2
R2
Number of Patients at Risk
R-chemo 517 496 487 481 470 453 298 193 115 32 0
R
Data cut-off31May2017.
Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R2) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWith Previously Untreated
FollicularLymphoma. Oral presentation at:American Society of ClinicalOncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.
2
(n = 513)
R-chemo
(n= 517)
Events, n (%) 38 (7) 31 (6)
3-year OS (95% CI)
HR (95% CI)
94% (91%-96%) 94% (91%-96%)
1.16 (0.72-1.86)